很少有研究发现他汀类药物的使用与头颈癌 (HNC) 结局之间存在关联。我们使用 1986 年至 2022 年间七家医院经过转换的观察性医疗结果合作伙伴关系 (OMOP) 通用数据模型 (CDM) 检查了他汀类药物使用对 HNC 复发的影响。在 9,473,551 名符合条件的患者中，我们确定了 4669 名 HNC 患者，其中 398 名患者患有 HNC 复发。倾向评分匹配后，4271 人被纳入目标队列，4271 人被纳入对照队列。使用 Cox 比例回归模型。在 4669 名患者中，398 名 (8.52%) 先前接受过他汀类药物处方。与倾向评分匹配对照相比，他汀类药物的使用与 3 年和 5 年 HNC 复发率降低相关（风险比 [RR]，0.79；95% 置信区间 [CI]，0.61-1.03；RR 0.89；95 % CI 分别为 0.70-1.12）。然而，他汀类药物的使用与 HNC 复发之间的关联并不具有统计学意义。基于亚组（包括年龄亚组）的复发荟萃分析显示出类似的趋势。这项倾向匹配队列研究的结果可能无法提供他汀类药物的使用与较低的 HNC 复发风险之间的统计学显着关联。有必要使用全国索赔数据和前瞻性研究进行进一步的回顾性研究。© 2023。作者。

Few studies have found an association between statin use and head and neck cancer (HNC) outcomes. We examined the effect of statin use on HNC recurrence using the converted Observational Medical Outcome Partnership (OMOP) Common Data Model (CDM) in seven hospitals between 1986 and 2022. Among the 9,473,551 eligible patients, we identified 4669 patients with HNC, of whom 398 were included in the target cohort, and 4271 were included in the control cohort after propensity score matching. A Cox proportional regression model was used. Of the 4669 patients included, 398 (8.52%) previously received statin prescriptions. Statin use was associated with a reduced rate of 3- and 5-year HNC recurrence compared to propensity score-matched controls (risk ratio [RR], 0.79; 95% confidence interval [CI], 0.61-1.03; and RR 0.89; 95% CI 0.70-1.12, respectively). Nevertheless, the association between statin use and HNC recurrence was not statistically significant. A meta-analysis of recurrence based on subgroups, including age subgroups, showed similar trends. The results of this propensity-matched cohort study may not provide a statistically significant association between statin use and a lower risk of HNC recurrence. Further retrospective studies using nationwide claims data and prospective studies are warranted.© 2023. The Author(s).